OSIP

CONSIDER LIGHTLY ADDING TO CANCER STOCK SHORTS ON THIS RALLY

www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD Every closed trade since 2007, without exception, is included in the performance results. Number of winning positions: 162 Number of losing positions: 10 Average annualized

Read More

STATUS OF CANCER STOCKS

Per our earlier post, we are short on OSIP from $32.2, SNTA from $3.50and EXEL from $5.35.We are long on PARD from $4.45 www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD Every closed

Read More

ENCOURAGING DATA AT ASCO

Our review of the data presented at 2009 Annual Meeting of the American Society of Clinical Oncology held in Orlando shows that the following stocks may move in response to the data:SNTA,ZIOP,CLDX,EXEL,BVTI,ABII,OGXI,INFI,OSIP AND PARD. If the opening prices are not too far from the close, consider scaling in the premarket

Read More

A fortune is to be made from AI stocks.
Get the list of 18 AI stocks to grab your share of the profits — no cost to you.

A fortune is to be made from AI stocks.

Get the list of 18 AI stocks to grab your share of the profits.

AI is a $1 Trillion Market

Making A Fortune
In Artificial Intelligence

Golden Age of Artificial Intelligence